Aptahem (publ) today announced the beginning of a collaboration with the University Health Network, a research hospital affiliated with University of Toronto in Canada. The collaboration aims to evaluate the anti-coagulant Apta-1 as an inhibitor of hyper inflammatory response...
Read MoreBioStock published an article on 1 July 2020 about Aptahem, which can be read in full below. At the end of last year, Aptahem entered a consortium with Örebro University with the aim of evaluating new strategies to reduce...
Read MoreAptahem (publ) is a biotech company developing aptamer-based pharmaceuticals for the treatment of life-threatening conditions, such as sepsis. A similar mechanism occurs in cardiovascular diseases where a combination of coagulation and inflammation are involved. Aptahem today announces that the...
Read MoreBioStock published an article on 24 June 2020 about Aptahem, which can be read in full below. For half a century Dexamethasone has been used to treat diseases such as rheumatoid arthritis and asthma. Four years ago, Malmö-based Aptahem...
Read MoreAptahem today informs that the company’s latest patent application has been registered in several countries and are subject to approval. The patent application, which is an international PCT application*, is a merger of two previous Europe applications and have...
Read MoreBioStock published an article on 29 April 2020 about Aptahem, which can be read in full below. Aptahem, whose primary drug candidate Apta-1 is being developed as an acute treatment for sepsis, recently announced that it is expanding its team...
Read MoreAptahem today announced that the company is expanding its team with Suzanne Kilany as Clinical Research Director for the next step in the development of the company’s lead drug candidate, Apta-1. Suzanne will primarily lead and coordinate the planning...
Read MoreBioStock published an article on 2 April 2020 about Aptahem, which can be read in full below. Aptahem has recently published an abstract containing data on its lead drug candidate Apta-1, which is being developed as an emergency treatment for...
Read MoreAptahem should have attended the ISICEM conference in Brussels these days, but it has been postponed until September 2020. The abstract that the Aptahem team should have presented at the conference has however now been published in the Critical...
Read MoreBioStock published an article on 16 March 2020 about sepsis and covid-19, which can be read in full below. A new study published in The Lancet shows that sepsis was the most common complication in more than half of...
Read More